Juvenile generalized pustular psoriasis treated with etanercept

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F14%3A10292749" target="_blank" >RIV/00216208:11130/14:10292749 - isvavai.cz</a>
Alternative codes found
RIV/00064211:_____/14:#0000388
Result on the web
<a href="http://dx.doi.org/10.1111/dth.12065" target="_blank" >http://dx.doi.org/10.1111/dth.12065</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/dth.12065" target="_blank" >10.1111/dth.12065</a>

Result language
angličtina
Original language name
Juvenile generalized pustular psoriasis treated with etanercept
Original language description
An 8-year-old boy with general pustular psoriasis (GPP) and iatrogenic secondary Cushing syndrome was treated successfully with etanercept after he had failed on acitretin, methotrexate, and methylprednisolone therapy. GPP is a severe and very rare variant of psoriasis in children often accompanied by life-threatening complications. Retinoids, cyclosporine, methotrexate, or dapsone used in a small number of case series and case reports were effective. Etanercept is a recombinant human tumor necrosis factor-alpha (TNF-alpha) receptor protein fused with Fc portion of IgG1 that binds to TNF-alpha, approved by Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis in children and teens who have not responded to other psoriasis treatments. In our patient, etanercept demonstrated significant clinical response associated with long-term efficacy without acute exacerbation, excellent tolerability, and good safety profile.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FO - Dermatology and venereology
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)